Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

(2016) Remo Panaccione et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Su1396 Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab

(2014) Christopher Ma et al.   GASTROENTEROLOGY

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study

(2014) Christopher Ma et al.   Journal of Crohns & Colitis

Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response

(2013) K. Sutharshan et al.   Journal of Crohns & Colitis

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

(2013) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

(2010) Cristina Nichita et al.   DIGESTION

Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients

(2010) Jason M. Swoger et al.   INFLAMMATORY BOWEL DISEASES

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

(2009) C. MA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas

(2009) Siew C Ng et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

(2008) A. SWAMINATH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT